Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorADARx Pharmaceuticals, Inc.
About this trial
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Eligibility criteria
Qualifiers
Mean eGFR greater than or equal to 30 mL/min/1.73m2
Clinical evidence of active kidney disease
Treated with supportive care including an ACE inhibitor or ARB if applicable
Willing to receive required vaccinations
Disqualifiers
Hereditary or acquired complement deficiency
Kidney transplant or renal replacement therapy
History of solid organ transplant
Other kidney disease
Trial design
Treatments tested in this trial
- ADX-038 Dose Level 2
- ADX-038 Dose Level 1
Treatment groups
45 Participants
are divided into 3 treatment groupsLocations
29Australia
ADARx Clinical Site2170, LiverpoolNew South Wales, Australia
ADARx Clinical Site2500, WollongongNew South Wales, Australia
ADARx Clinical SiteNSW 2139, Sydney Australia
ADARx Clinical SiteQLD 4102, Woolloongabba Australia
Sponsors and collaborators
ADARx Pharmaceuticals, Inc.
Lead sponsor
Source ClinicalTrials.gov